Reeling from PD-1 slapdown, Incyte stirs concerns with side effects of oral PD-L1 — although drug is also 'clearly active'
The rejection of its PD-1 inhibitor, retifanlimab, was never going to be the end of Incyte’s checkpoint story. Not only was the biotech holding out hope of changing the FDA’s mind and testing the cancer drug in multiple combinations, it also lined up a trio of oral PD-L1 candidates as next-gen contenders for the megablockbuster market.
But a surprise side effect that cropped up in a Phase I trial could cast a cloud on the lead oral PD-L1 blocker.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.